Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 4, 2012, Pages 296-305

  Amit, Doron ^a   Hochberg, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diphtheria toxin A; Glioblastoma; H19; Hepatocellular carcinoma; IGF2; Ovarian cancer; Pancreatic cancer; Targeted cancer therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN A FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; GENE; GENE EXPRESSION; GLIOBLASTOMA; H19 GENE; HUMAN; HUMAN CELL; IGF2 P4 GENE; IN VITRO STUDY; LIFESPAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; QUALITY OF LIFE; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALIA;

EID: 84866016111     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abulail R, Hochberg A and Galun E. The H19 noncoding RNA is essential for human tumor growth. PLoS ONE 2007; 2: e845.
2. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E and Hochberg A. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443-451.
3. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T and Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-273.
4. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, De-Groot N and Hochberg A. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995; 45: 335-338.
5. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, Hochberg A and Ayesh S. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21-25.
6. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S, Schneider T, de Groot N and Hochberg A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003; 7: 535-541.
7. Matouk I OP, Ayesh S, Sidi A, Czerniak A, de Groot N, Hochberg A The oncofetal H19 RNA in human cancer, from the bench to the patient. Cancer Therapy 2005; 3: 249-266.
8. Erdmann VA, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N and Barciszewski J. The non-coding RNAs as riboregulators. Nucleic Acids Res 2001; 29: 189-193.
9. Ariel I, Ayesh S, Perlman EJ, Pizov G, Tanos V, Schneider T, Erdmann VA, Podeh D, Komitowski D, Quasem AS, de Groot N and Hochberg A. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol 1997; 50: 34-44.
10. Engstrom W, Shokrai A, Otte K, Granerus M, Gessbo A, Bierke P, Madej A, Sjolund M and Ward A. Transcriptional regulation and biological significance of the insulin like growth factor II gene. Cell Prolif 1998; 31: 173-189.
11. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM and Sussenbach JS. Differential expression of the human, mouse and rat IGF-II genes. Regul Pept 1993; 48: 77-89.
12. de Pagter-Holthuizen P, Jansen M, van der Kammen RA, van Schaik FM and Sussenbach JS. Differential expression of the human insulinlike growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. Biochim Biophys Acta 1988; 950: 282-295.
13. Holthuizen P, van der Lee FM, Ikejiri K, Yamamoto M and Sussenbach JS. Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Biochim Biophys Acta 1990; 1087: 341-343.
14. Ekstrom TJ, Cui H, Li X and Ohlsson R. Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 1995; 121: 309-316.
15. Giannoukakis N, Deal C, Paquette J, Goodyer CG and Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993; 4: 98-101.
16. Ohlsson R and Franklin G. Normal development and neoplasia: the imprinting connection. Int J Dev Biol 1995; 39: 869-876.
17. Morison IM and Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998; 4: 110-115.
18. Wu HK, Squire JA, Catzavelos CG and Weksberg R. Relaxation of imprinting of human insulinlike growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997; 235: 123-129.
19. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, Lee OH, Park BC and Kim KW. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 1999; 59: 5989-5994.
20. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Schwartz P and Yu H. Promoterspecific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol 2006; 103: 990-995.
21. Mineo R, Fichera E, Liang SJ and Fujita-Yamaguchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochem Biophys Res Commun 2000; 268: 886-892.
22. Sohda T, Yun K, Iwata K, Soejima H and Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996; 75: 307-311.
23. Leighton PA, Saam JR, Ingram RS, Stewart CL and Tilghman SM. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 1995; 9: 2079-2089.
24. Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D, Libdeh BA, Levy C, Birman T, Tykocinski ML, de Groot N and Hochberg A. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000; 53: 320-323.
25. Amit D and Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 2010; 8: 134.
26. Ohana P, Kopf E, Bibi O, Ayesh S, Schneider T, Laster M, Tykocinski M, de Groot N and Hochberg A. The expression of the H19 gene and its function in human bladder carcinoma cell lines. FEBS Lett 1999; 454: 81-84.
27. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL and Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002; 62: 6442-6446.
28. Kaplan R, Luettich K, Heguy A, Hackett NR, Harvey BG and Crystal RG. Monoallelic upregulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers. Cancer Res 2003; 63: 1475-1482.
29. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR and Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006; 4: 283-292.
30. Ariel I, Lustig O, Oyer CE, Elkin M, Gonik B, Rachmilewitz J, Biran H, Goshen R, de Groot N and Hochberg A. Relaxation of imprinting in trophoblastic disease. Gynecol Oncol 1994; 53: 212-219.
31. Pavelic K, Bukovic D and Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002; 8: 771-780.
32. Bates P, Fisher R, Ward A, Richardson L, Hill DJ and Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995; 72: 1189-1193.
33. Moorehead RA, Sanchez OH, Baldwin RM and Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 2003; 22: 853-857.
34. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K and Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-13784.
35. Kawamoto K, Onodera H, Kondo S, Kan S, Ikeuchi D, Maetani S and Imamura M. Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology 1998; 55: 242-248.
36. Takanami I, Imamuma T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 1996; 61: 205-208.
37. Christofori G, Naik P and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369: 414-418.
38. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S and Fujita-Yamaguchi Y. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998; 291: 469-479.
39. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D and Hassan AB. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005; 205: 145-153.
40. Yu H and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
41. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO and Horwitz SB. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010; 16: 2999-3010.
42. Fichera E, Liang S, Xu Z, Guo N, Mineo R and Fujita-Yamaguchi Y. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 2000; 10: 61-70.
43. Kawamoto K, Onodera H, Kan S, Kondo S and Imamura M. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999; 85: 18-25.
44. Biran H, Ariel I, de Groot N, Shani A and Hochberg A. Human imprinted genes as oncodevelopmental markers. Tumour Biol 1994; 15: 123-134.